India's pharma exports face pressure from Trump's tariff threats

Indian pharmaceutical exports to the U.S. market are facing increasing pressure due to threats from the Trump administration to impose high tariffs on imports of generic medicines. The plan includes introducing a 100% tariff starting in 2028, with the possibility of increasing it to 200% the following year, aiming to encourage companies to manufacture drugs domestically within the United States and reduce reliance on imports. This threat presents a significant challenge for Indian pharmaceutical companies that depend on low-cost production for treating chronic diseases like diabetes and cancer, as the U.S. accounts for about 37% of India's pharmaceutical exports, which totaled $26 billion in 2025. These companies are also confronted with difficulties in relocating production to the U.S. due to high costs and limited profit margins, despite substantial investments in the American market—factors that could lead to increased drug prices for American consumers. Additionally, the pressures might push Indian firms to shift toward more profitable sectors such as biopharmaceuticals and specialized therapies. Sources expect that U.S. policy might be revised before implementation in light of upcoming political changes.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل